Reply to J. Edeline et al

J Clin Oncol. 2022 Nov 1;40(31):3668. doi: 10.1200/JCO.22.01283. Epub 2022 Jul 5.

Authors

John Bridgewater¹, Peter Fletcher¹, John Primrose¹; BILCAP Study Group

Affiliation

¹ John Bridgewater, MD, PhD, UCL Cancer Institute, London, United Kingdom; Peter Fletcher, MSc, Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom; and John Primrose, MD, University of Southampton, Southampton, United Kingdom.

PMID: 35787066
DOI: 10.1200/JCO.22.01283

No abstract available

Publication types

Letter
Comment

Grants and funding

25354/CRUK_/Cancer Research UK/United Kingdom